Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus–infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir

El‐Karaksy, Hanaa; Mogahed, Engy A.; Abdullatif, Hala; Ghobrial, Carolyne; El-Raziky, Mona; El-Koofy, Nehal; El-Shabrawi, Mortada; Ghita, Haytham; Baroudy, Sherif; Okasha, Sawsan

doi:10.1097/mpg.0000000000002101

Cited by 36 publications

(38 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excellent efficacy (SVR12 99%) and safety profile of this regimen was confirmed in two further Egyptian studies enrolling 184 adolescents with HCV genotype 4 infection. 83,84 Sofosbuvir and weight-based ribavirin was studied for 12 weeks in 52 adolescents with genotype 2 or 3 infection. 9 SVR rates were 100% (13/13) in genotype 2 and 97% (38/39) in genotype 3 patients.…”

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Indolfi

Easterbrook

Dusheiko

et al. 2019

The Lancet Gastroenterology & Hepatology

135

147

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide. Short-course, oral, curative, direct-acting antiviral regimens have now transformed treatment for HCV infection. Since the launch in 2016 of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on treatment of adults, who bear the greatest burden of morbidity and mortality of HCV related chronic liver disease. There has been much less attention paid to addressing response to HCV in children and adolescents, in part because of the lack of data to inform specific paediatric management practices and policy. In this review, we summarize current knowledge on epidemiology, natural history, and treatment of chronic HCV infection in adolescents and children, and highlight key differences from infection acquired in adulthood. The estimated global prevalence and burden in children aged 1 to 19 years is 0•15% and 3•5 (3•1-3•9) million, respectively. HCV infection is usually asymptomatic during childhood, and cirrhosis and hepatocellular carcinoma are rare. Sofosbuvir, ledipasvir and ribavirin have now received regulatory approval and guidelines recommend their use in adolescents ages >12 years with HCV infection. Key actions to address the current policy gaps and achieve treatment scale-up comparable to that in adults include: establishment of a testing and treatment access campaign targeted at children and adolescents; fast-track evaluation of pangenotypic regimens and accelerated approval of paediatric formulations. Research gaps that need to be addressed include age-specific seroprevalence studies of HCV viraemia in priority countries; further validation of non-invasive tests in children; and establishment of paediatric treatment registries and international consortia to promote collaborative research agenda.

show abstract

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Indolfi

Easterbrook

Dusheiko

et al. 2019

The Lancet Gastroenterology & Hepatology

135

147

View full text Add to dashboard Cite

show abstract

“…Three clinical trials supporting the approval of ledipasvir/sofosbuvir in the pediatric population aged ≥ 3 years demonstrated high SVR12 rates comparable to those observed in adults . Limited real‐world data further corroborate these findings …”

Section: Hcv In the Pediatric Populationmentioning

confidence: 96%

“…(281)(282)(283) Limited real-world data further corroborate these findings. (284,285) In September 2019, the FDA approved weightbased sofosbuvir plus ribavirin for treatment-naive and interferon-experienced (± ribavirin) children aged ≥ 3 years with genotype 2 or 3, without cirrhosis or with compensated cirrhosis (Child-Pugh A). A 12-week course is recommended for pediatric patients without cirrhosis, and 24 weeks is recommended for those with compensated cirrhosis (see the online HCV guidance for dosing recommendations).…”

Section: An 8-week Course Of the Daily F Ixed-dose Combination Of Glementioning

confidence: 99%

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

2020

View full text Add to dashboard Cite

“…51,52 In HCV-infected 12 to 17year-olds who received oral fixed-dose combinations of sofosbuvir and ledipasvir daily for 12 weeks, tests for HCV RNA gave negative results in all patients at weeks 8 and 12 and at SVR12. 53 In these patients, asthenia was the most common adverse effect, followed by headache. No symptoms related to the cardiovascular system or cases of symptomatic bradycardia/syncope were reported.…”

Section: Treatment Of Children With Hcv Infectionmentioning

confidence: 98%

Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments

Ragusa¹,

Corsaro

Frazzetto

et al. 2020

AJP Rep

View full text Add to dashboard Cite

Objective The aim of the paper is to review the current information relating to the diagnosis and treatment of hepatitis C virus (HCV) infection in pregnant women and children, particularly those infected by mother-to-child transmission. Study Design A review of published literature was performed to identify relevant articles published between January 2015 and March 2019 on: HCV infection in pregnant woman, mother-to child-transmission of HCV and HCV infection in pediatrics. The results of the evaluation of the different studies were summarized in two sections describing separately the screening and effective treatments in pregnant women and children. Results The rate of mother-to-child transmission of HCV is approximately 5%. HCV infection is strongly associated with cholestasis and preterm birth. Prenatal diagnosis of hepatitis C virus has a dual benefit for mother and child. Perinatally infected children develop cirrhosis in earlier age than those who acquire HCV as adolescents. Pregnant women with cirrhosis have a higher risk of poor maternal and neonatal outcomes than those without cirrhosis. Conclusion To improve public health, universal screening of pregnant women for HCV infection should be performed. Early identification of women and children with HCV infection is important to enable them to be included in assessment and/or treatment programs.

show abstract

Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus–infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir

Abstract: Treatment with all-oral DAAs (SOF/LED) for 12 weeks was well tolerated in Egyptian children and adolescents infected with genotype 4 HCV, with 100% SVR12 and negligible side effects.

Cited by 36 publications

References 28 publications

Hepatitis C virus infection in children and adolescents

Hepatitis C virus infection in children and adolescents

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments

Contact Info

Product

Resources

About